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Clinical question: What is the best management approach for gynecomastia?
Results: In most patients, surgical correction usually leads to immediate cosmetic and symp-
tomatic improvement and is considered the best approach. In men who are being treated with 
antiandrogen therapies, pharmacological intervention with tamoxifen is the most effective 
approach, followed by radiotherapy.
Implementation: Pitfalls to avoid when treating gynecomastia
•	 Failure to detect the very rare male breast cancer
•	 Overly aggressive early intervention or evaluation
•	 Appropriate medical intervention
•	 When to refer to specialist treatment
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Gynecomastia
Definition: Gynecomastia is the benign proliferation of the glandular tissue in the 
male breast beneath the nipple (subareolar region). True gynecomastia is typically a 
rubbery or firm mound of tissue that is concentric with the nipple-areolar complex. 
This is to be distinguished from pseudogynecomastia, which lacks such a disk of 
tissue, as it is an increase in subareolar fat without enlargement of the breast glandular 
component. In about half of the cases, the process is clinically bilateral. Most cases 
are benign. Diagnostic evaluation is needed only when the palpable mass is unilateral, 
hard, fixed, peripheral to the nipple, or associated with nipple discharge, skin changes, 
or lymphadenopathy.1,2
Etiology: Gynecomastia is likely caused by an imbalance between increased estrogen 
activity and decreased androgen activity at the breast tissue level. Several medical 
conditions are associated with gynecomastia such as primary or secondary gonadal 
failure, androgen resistance syndromes, hyperthyroidism, chronic liver disease, use 
of some medications such as spironolactone, digoxin, bicalutamide, cimetidine and 
drugs of abuse such as alcohol and marijuana.1,2
Incidence: Prevalence of asymptomatic gynecomastia is 60%–90% in neonates, 
50%–60% in adolescents, and up to 70% in men age 50–69 years.3–6 Trimodal 
distribution for asymptomatic gynecomastia is noted (neonatal, pubertal, and in elderly 
males). Prevalence of symptomatic gynecomastia is markedly lower.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Economics: No previous study has evaluated the economic 
burden of gynecomastia, but aggressive unnecessary work up 
in low risk cases, which are the most common, can be costly.
Level of evidence used in this summary: RCTs, sys-
temic reviews, and observational studies.
Search sources: MEDLINE, EMBASE, the Cochrane 
Database of Systematic Reviews, the Cochrane Register of 
Controlled Trials, ISI Web of Science and Scopus.
Outcomes:
1	 Identification of underlying medical conditions or associ-
ated medications
2	 Resolution of breast pain
3	 Cosmesis (decreased breast size)
5	 Identification of the rare cases of male breast cancer
4	 Resolution of psychological impact of gynecomastia
6	 Avoidance of excessive laboratory and radiologic 
evaluation
Consumer summary: Gynecomastia is the development of 
glandular and ductal tissue in the male breast. It is typically 
caused by an imbalance of the action of estrogens (female 
hormones) and androgens (male hormones) on the breast 
tissue. A variety of medications, medical conditions and 
age-related factors can cause or contribute to this condition. 
The condition is generally benign and if it does not resolve 
spontaneously, can be effectively treated.
Summary of RCTs
Author Number randomized Population Interventions Results
Ozen8 125 Men on AA RT vs no RT RT best; P , 0.001
Fradet9 282 Men on AA tamoxifen (different dosing schedules) 20 mg/day better than smaller doses
Saltzstein10 107 Men on AA tamoxifen vs anastrozole tamoxifen better
Perdonà11 51 Men on AA tamoxifen vs RT tamoxifen better than RT
Di Lorenzo12 102 Men on AA tamoxifen vs RT tamoxifen better than RT
Boccardo13 114 Men on AA tamoxifen vs anastrozole tamoxifen better than anastrozole
Tyrrell14  106 Men on AA RT vs sham RT RT better; P , 0.001
Abbreviations: AA, anti-androgen drugs; RT, radiotherapy
The evidence
What is the best treatment for gynecomastia in men taking 
antiandrogen therapies for prostate cancer?
The systematic review7 concluded that serum estrogen 
receptor modulators (SERMS, e.g. tamoxifen), aromatase 
inhibitors (AIs, e.g. anastrazole), radiotherapy (RT) or both, 
prevent or reduce gynecomastia and breast pain associated 
with antiandrogen (AA) use. Of the three options, tamoxifen 
is most effective.
Systematic reviews  1
RCTs  8
Conclusions
Serum estrogen receptor modulators, particularly tamoxifen, 
or radiotherapy may help prevent or reduce gynecomastia in 
men taking antiandrogen therapies.
What is the best treatment for gynecomastia in all other 
males (not taking antiandrogen therapies)?
RCT  1
Case series: multiple
No high quality evidence exists to support a role for 
pharmacological agents or radiotherapy in this setting. Case 
series showed reduction in glanular tissue size after using 
SERMS (e.g. tamoxifen or raloxifene).
Surgical correction is considered the gold standard 
treatment. Although similar to pharmacological interventions, 
surgical correction has been tested only in case series and 
not in randomized trials. Published case series demon-
strates clinical success with cosmetic, symptomatic, and 
psychological improvements with minimal adverse effects.
Surgery can be either
1)  more invasive (ie, subcutaneous mastectomy that involves 
the direct resection of the glandular tissue using a peri-
areolar or transareolar approach, with or without associ-
ated liposuction).
2)  less invasive techniques that require minimal surgical 
incision utilizing an axillary approach and endoscopic 
visualization and resection.
No high quality evidence exists to support one surgical 
approach over the other.
Conclusion
Surgery is the gold standard therapy for symptomatic 
gynecomastia in most patients.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Decision about pursuing therapy
Asymptomatic gynecomastia is a common and physiologic 
finding at three stages of the life of men and does not require 
intervention. Symptomatic gynecomastia in adult males can 
be efficiently diagnosed and reassurance and/or interventions 
can readily be initiated.
In general, the decision to treat gynecomastia depends on 
the values and preferences of the patient and on the impact of 
gynecomastia on their quality of life. If no improvement is noted 
after the withdrawal of causative medications or treatment of the 
associated underlying medical conditions, surgical correction, 
pharmacological therapies, or radiotherapy can be considered.
Summary of RCTs
Author Number randomized Population Interventions Results
Plourde15 80 Boys 11–18 years anastrozole null results
Summary of selected case series
Author Sample size Interventions Results
Prado16 25 minimally invasive surgery All had good results with no complications or need 
for revision
Handschin17 100 (160 procedures) subcutaneous mastectomy All had good results, revision rate 7% and early 
surgical complication rate 31%
Alagaratnam18 61 40 mg of tamoxifen daily for 1–4 months 80% complete regression. no long-term side 
effects over a follow-up of 36 months
Lawrence19 38 3- to 9-month course of tamoxifen or raloxifene Both groups had significant reduction in breast size. 
no side effects in any patients
Derman20 37 tamoxifen Pain and size reduction was seen 
in all patients
The practice
Potential pitfalls
•	 All masses that are not located in the subareolar (under 
the nipple) area should be evaluated further for the pos-
sibility of male breast cancer.
•	 Pseudogynecomastia (the presence of fatty tissue only 
in the breasts) associated with obesity, does not require 
evaluation or treatment.
Management
Gynecomastia can generally be managed by non-specialists. 
Indications for specialist referral are given below.
Assessment
A thorough history and physical examination should exclude 
pseudogynecomastia. History should include all medications, 
supplements, hormones, and drugs of abuse including alcohol 
and marijuana. Diagnostic evaluation is needed only when 
the palpable mass is unilateral, hard, fixed, peripheral to the 
nipple, or associated with nipple discharge, skin changes, or 
lymphadenopathy.
•	 If a mass is palpated in an eccentric area (non-subareolar), 
mammography is quite accurate in distinguishing 
malignant from benign male breast disease and 
substantially reduces the need for biopsy. Sensitivity and 
specificity of mammography for benign and malignant 
breast conditions exceeds 90%.
•	 If palpable scrotal mass is present, scrotal ultrasound 
imaging is recommended.
•	 Basic laboratory evaluation includes blood profile for 
liver, kidney, and thyroid function to exclude respective 
medical conditions. Hormonal blood levels for total and 
bioavailable testosterone, estradiol, prolactin, leuteinizing 
hormone, and human chorionic gonadotropin can direct 
evaluation toward pituitary, gonadal, or extra gonadal 
endocrinopathies and neoplasms.
•	 If all testing is unrevealing, idiopathic gynecomastia is 
diagnosed.
Treatment
Gynecomastia is a benign condition and usually self-limited.
•	 Over time fibrotic tissue replaces symptomatic proliferation 
of glandular tissue and tenderness resolves.
•	 If history, physical, and lab studies do not reveal an 
underlying pathology, reassurance and periodic follow-up 
are recommended.
•	 Causative medications or supplements should be 
withdrawn and underlying causative medical conditions, 
e.g. hyperthyroidism, should be addressed as a first step.Therapeutics and Clinical Risk Management
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•	 If gynecomastia persists and is associated with pain 
and/or psychological distress and the patient wishes to 
pursue treatment, pharmacologic and surgical options are 
available.
•	 Pharmacologic therapy is likely beneficial if implemented 
in the first several months before fibrous tissue replaces 
glandular tissue, a process that is irreversible.
•	 The efficacy of pharmacotherapy is supported by low 
quality evidence SERMs, e.g. tamoxifen or raloxifene, and 
more recently aromataste inhibitors, e.g. anastrozole.
•	 Surgical correction in benign gynecomastia is done 
primarily for cosmetic indications (see indications for 
specialist referral).
Indications for specialist referral
•	 Patient has significant persistent bilateral or asymmetric 
unilateral breast development of cosmetic concern.
•	 Further enlargement of the male breast despite appropriate 
medical intervention.
•	 Psychological distress for patient due to breast 
appearance.
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